Tivanisiran, a novel siRNA for the treatment of dry eye disease.

@article{MorenoMontas2018TivanisiranAN,
  title={Tivanisiran, a novel siRNA for the treatment of dry eye disease.},
  author={Javier Moreno-Monta{\~n}{\'e}s and Anne-Marie Bleau and Ana I. Jim{\'e}nez},
  journal={Expert opinion on investigational drugs},
  year={2018},
  volume={27 4},
  pages={421-426}
}
INTRODUCTION Dry eye disease (DED) is characterized by an alteration of the tear film with ocular inflammation and neurosensory abnormalities. The main clinical signs of this condition are tear instability and ocular damage. Although DED has gained significant attention in the past few years, limited prescription treatment options are available for patients… CONTINUE READING